Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT.

[1]  J. Wagner,et al.  Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning , 2021, Blood advances.

[2]  C. Brunstein,et al.  Guidelines for Infection Prophylaxis, Monitoring and Therapy in Cord Blood Transplantation. , 2021, Transplantation and cellular therapy.

[3]  M. Perales,et al.  Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis. , 2021, Blood.

[4]  J. Wagner,et al.  Low 5-year health care burden after umbilical cord blood transplantation. , 2021, Blood advances.

[5]  S. Devine,et al.  Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products , 2020, Transplantation and Cellular Therapy.

[6]  P. Chevallier,et al.  Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. , 2020, Blood advances.

[7]  E. Leifer,et al.  Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). , 2020, Blood.

[8]  S. Hekmatimoghaddam,et al.  Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia , 2020, Cancer management and research.

[9]  J. Esteve,et al.  Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients , 2020, Bone Marrow Transplantation.

[10]  C. Solano,et al.  Prospective randomized study comparing myeloablative unrelated umbilical-cord blood transplant versus HLA-haploidentical related stem cell transplant for adults with hematologic malignancies. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  S. Montoto,et al.  Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. , 2019, The Lancet. Haematology.

[12]  D. Venzon,et al.  Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. , 2019, The Journal of clinical investigation.

[13]  S. Montoto,et al.  Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report , 2017, Bone Marrow Transplantation.

[14]  P. Westervelt,et al.  Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[15]  H. Einsele,et al.  Impact of Atg-containing Reduced-intensity Conditioning after Single-or Double-unit Allogeneic Cord Blood Transplantation on Behalf of Eurocord and the European Society for Blood and Marrow Transplantation Key Points , 2022 .

[16]  J. Sierra,et al.  Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia , 2015, Leukemia.

[17]  M. Labopin,et al.  Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT , 2014, Leukemia.

[18]  J. Klein,et al.  Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. , 2014, Blood.

[19]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[20]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[21]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  S. Hirschfeld,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[24]  J P Klein,et al.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[26]  D.,et al.  Regression Models and Life-Tables , 2022 .